Skip to content
HowShorted

Perspective Therapeutics, Inc. short interest in 2019

In 2019, Perspective Therapeutics, Inc.'s disclosed short interest ran from 1.63% of shares outstanding on 15 Jan 2019 to 2.45% on 31 Dec 2019, a change of +0.82 percentage points. The year's high was 2.61% on 13 Dec 2019 and its low 0.74% on 31 Jul 2019, averaging 1.53% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.37 days on 15 Oct 2019. Full history: Perspective Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Perspective Therapeutics, Inc. in 2019

2019 in figures

Start of year
1.63% (15 Jan 2019)
End of year
2.45% (31 Dec 2019)
Change
+0.82 pp
High
2.61% (13 Dec 2019)
Low
0.74% (31 Jul 2019)
Average
1.53%
Highest days to cover
18.37 (15 Oct 2019)
SEC filings marked
8

Every report in 2019

Perspective Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20191.63%10.83
31 Jan 20191.58%3.05
15 Feb 20191.52%4.54results (8-K), 10-Q filed
28 Feb 20191.38%3.23
15 Mar 20191.31%11.21
29 Mar 20191.26%9.96
15 Apr 20191.23%6.83
30 Apr 20191.15%4.32
15 May 20191.28%6.06results (8-K), 10-Q filed
31 May 20190.97%2.93
14 Jun 20191.03%5.78
28 Jun 20190.87%6.37
15 Jul 20190.94%8.96
31 Jul 20190.74%5.46
30 Sep 20192.04%4.05results (8-K), 10-K filed
15 Oct 20191.98%18.37
31 Oct 20191.94%17.91
15 Nov 20192.04%4.98results (8-K), 10-Q filed
29 Nov 20192.27%2.32
13 Dec 20192.61%2.46
31 Dec 20192.45%7.04

See also: Perspective Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.